Ahmadieh Hamid, Moradian Siamak, Malihi Mohsen
Department of Ophthalmology, Ophthalmic Research Center, Labbafinejad Medical Center, Shaheed Beheshti Medical University, Boostan 9 St., Pasdaran Ave., Tehran, 16666, Iran.
Int Ophthalmol. 2005 Aug-Oct;26(4-5):191-3. doi: 10.1007/s10792-007-9036-y. Epub 2007 Feb 8.
To report the rapid regression of extensive retinovitreal neovascularization following the administration of a single dose of intravitreal bevacizumab.
A 60-year-old woman presented with recurrent vitreous hemorrhage originating from active retinovitreal neovascularization secondary to branch retinal vein occlusion. The neovascular tissue remained active despite multiple sessions of laser therapy. Intravitreal injection of 1.25 mg bevacizumab was performed.
Rapid regression of the retinovitreal neovascularization, a marked reduction in retinal vein engorgement, and visual improvement was observed 1 week after the intervention
Intravitreal bevacizumab can result in the rapid and dramatic regression of retinovitreal neovascularization refractory to previous laser photocoagulation.
报告单次玻璃体内注射贝伐单抗后广泛视网膜玻璃体新生血管的快速消退情况。
一名60岁女性因视网膜分支静脉阻塞继发的活跃视网膜玻璃体新生血管导致反复玻璃体积血就诊。尽管进行了多次激光治疗，新生血管组织仍很活跃。进行了1.25毫克贝伐单抗的玻璃体内注射。
干预后1周观察到视网膜玻璃体新生血管快速消退、视网膜静脉充血明显减轻以及视力改善。
玻璃体内注射贝伐单抗可使先前激光光凝治疗无效的视网膜玻璃体新生血管快速且显著消退。
